Navigation Links
Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer

SEATTLE, July 23 /PRNewswire/ -- Sound Pharmaceuticals (SPI) has filed an Investigational New Drug Application with the FDA for the clinical testing of a proprietary formulation of ebselen for the prevention of chemotherapy induced hearing loss or ototoxicity. The oral capsule containing ebselen, SPI-3005, will be tested in advanced stage lung cancer and head and neck cancer patients receiving platinum based chemotherapy. This marks the second development program for SPI to enter clinical testing for a hearing loss indication. Last year, SPI-1005, an oral capsule containing ebselen entered Phase II testing with the US Navy for the prevention and treatment of noise induced hearing loss.

Currently there are no FDA approved drugs for the prevention and treatment of drug induced hearing loss or ototoxicity. SPI hopes to address this unmet medical need with its first in class first in indication drug. Several different research groups have shown that chemotherapy treatment reduces glutathione peroxidase (GPx) activity in the mammalian inner ear resulting in hearing loss, tinnitus, vertigo and dizziness. GPx is the dominant catalytic antioxidant enzyme within the inner ear, and a loss of its activity results in irreparable damage to hair cells, neurons and non-sensory tissues that are critical for hearing and balance. "A dose limiting side effect of platinum based chemotherapies are their devastating ototoxicity and neurotoxicity, and SPI-3005 is designed to attenuate these side effects without inhibiting the therapeutic efficacy of platinum or taxane based chemotherapies," said VP Eric Lynch, PhD.

"Otoprotectants such as SPI-3005 have the potential to reduce and/or alleviate chemotherapy-induced ototoxicity, and clinical studies should be pursued," said Stephen Fausti, PhD, and Director of the National Center for Rehabilitative Auditory Research (NCRAR) at the Portland VA, Professor of Otolaryngology and Neurology at Oregon Health Sciences University.

Sound Pharmaceuticals, Inc., is a privately held biopharmaceutical company with a focus on developing the first drugs for hearing loss and brain injury. For more information please contact Jonathan Kil, MD, President and CEO, 206-634-2559 or

SOURCE Sound Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Actress and New Mom Keri Russell Joins PKIDs to launch Silence the Sounds of Pertussis Campaign
2. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
3. Adding Breast Ultrasound Screening to Mammography Reveals Cancers not Seen on Mammography Alone in Women at Increased Risk for Breast Cancer
4. Applisonix Announces Breakthrough in Ultrasound Technology for Hair Removal - Average Hair Reduction of 38% Following Initial Treatment
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. ( Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
(Date:10/13/2015)... 13, 2015 TriGuard™ Cerebral Protection ... findings from the multicenter Neuro-TAVR study with the clinical ... San Francisco this week. --> ... will be sharing additional findings from the multicenter Neuro-TAVR ... (TCT) meeting in San Francisco ...
(Date:10/13/2015)... According to the 2015 National ... Cardinal Health , achieving both higher patient ... revenue streams are vital to the future success ... Digest affirms that independent community pharmacies are ... inner city and rural areas," said NCPA CEO ...
(Date:10/13/2015)... WASHINGTON , Oct. 13, 2015  Measurement ... quality improvement and balancing financial incentives, but gaps ... improve patient care and health systems. A new, ... Journal of Managed Care explores measurement ... improve measure sets. --> ...
Breaking Medicine Technology:
(Date:10/13/2015)... Pennsylvania (PRWEB) , ... October 13, 2015 , ... ... people through a unique private messaging application, announced today a significant contract that ... another five years. Independence plans to build on the growing success of its ...
(Date:10/13/2015)... , ... October 13, 2015 , ... A child without ... why SmileCareClub , the leading remote invisible aligner system, has joined with ... otherwise go without it. For each aligner treatment plan purchased, SmileCareClub will donate one ...
(Date:10/13/2015)... , ... October 13, 2015 ... ... Omega-3, a first-of-its kind product that targets the unique health needs of ... of the American Pregnancy Association ( ), utilizes Nordic Naturals’ exclusive, ...
(Date:10/13/2015)... ... ... Tempe Dental Care, a leading Tempe dentists’ office, celebrates offering gentle, pain free ... more than 5 years. A leading cause of emergency room visits, school absences, and ... timely. , Sedation dentistry provides an anxiety-free dental experience with safe ...
(Date:10/13/2015)... ... October 13, 2015 , ... According to an ... an orbital fracture when a teammate accidentally elbowed him in the left eye during ... eye injury is just one of a series of setbacks, including a knee injury ...
Breaking Medicine News(10 mins):